ClinicalTrials.gg
CompletedNCT03012165Updated Jan 9, 2023Results posted

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

A Phase 2 interventional study of ADX-102 Ophthalmic Drops (0.5%) and ADX-102 Ophthalmic Drops (0.1%) in Conjunctivitis, Allergic, sponsored by Aldeyra Therapeutics, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-09.

Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.

Enrollment
24th of 90
154 · median 94
Started
2016
with 1 other
Phase 2
25 of 95
4 open now
Registered
65th of 95
by date
Lead sponsor
3 of 95
Aldeyra Therapeutics, Inc.

Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 24th largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2016, is one of 25 in phase 2, and was the 65th registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 18 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Conjunctivitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.

03

Conditions studied

  • Conjunctivitis, Allergic

Keywords

  • ADX-102
  • Allergic Conjunctivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be at least 18 years of age of either gender and any race
  • have a positive history of ocular allergies and a positive skin test reaction to a seasonal (grasses, ragweed, and/or trees) or perennial allergen (cat dander, dog dander, dust mites, cockroach) as confirmed by an allergic skin test within the past 24 months
  • have a calculated visual acuity of 0.7 logMAR or better in each eye as measured using an ETDRS chart

Exclusion criteria

Exclusion Criteria:

  • have known or sensitivities to the use of the product or any of its components
  • have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters (including but not limited to narrow angle glaucoma, blepharitis, follicular conjunctivitis, iritis, pterygium or a diagnosis of dry eye)
  • have had ocular surgical intervention within three (3) months prior to Visit 1 or during the study and/or a history of refractive surgery within the past six (6) months
  • have a known history of retinal detachment, diabetic retinopathy, or active retinal disease
  • have the presence of an active ocular infection (bacterial, viral or fungal) or positive history of an ocular herpetic infection at any visit
  • be a female who is currently pregnant, planning a pregnancy, lactating, not using a medically acceptable form of throughout the study duration and for 14 days prior to the installation of investigational product, or has a positive urine pregnancy test at Visit 1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    ADX-102 Ophthalmic Drops (0.5%)

    ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.

    Drug: ADX-102 Ophthalmic Drops (0.5%)

  • Experimental
    ADX-102 Ophthalmic Drops (0.1%)

    ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.

    Drug: ADX-102 Ophthalmic Drops (0.1%)

  • Placebo comparator
    Vehicle of ADX-102 Ophthalmic Drops

    Vehicle of ADX-102 Ophthalmic Drops

    Drug: Vehicle of ADX-102 Ophthalmic Drops

Interventions

06

What researchers measure

Primary outcomes

  1. Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.

    Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.

    Time frame: Efficacy assessment period (Day 1 through Day 15), Day 15 reported.

  2. Ocular Itching Evaluated by the Subject at 15(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.

    Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.

    Time frame: Efficacy assessment period (Day 1 through Day 15), Day 15 reported.

  3. Ocular Itching Evaluated by the Subject at 20(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.

    Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.

    Time frame: Efficacy assessment period (Day 1 through Day 15), Day 15 reported.

07

Results

Posted Jan 9, 2023

Participant flow

Participant flow — Overall Study
MilestoneADX-102 Ophthalmic Drops (0.5%)ADX-102 Ophthalmic Drops (0.1%)Vehicle of ADX-102 Ophthalmic Drops
Started535150
Completed514949
Not completed221

Outcome measures

PrimaryOcular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.

Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.

Time frame:
Efficacy assessment period (Day 1 through Day 15), Day 15 reported.
Reported as:
Mean · units on a scale
Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.
units on a scaleADX-102 (0.5%)ADX-102 (0.1%)Vehicle
Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.2.020 ± 0.98212.398 ± 0.82902.515 ± 0.9661
PrimaryOcular Itching Evaluated by the Subject at 15(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.

Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.

Time frame:
Efficacy assessment period (Day 1 through Day 15), Day 15 reported.
Reported as:
Mean · units on a scale
Ocular Itching Evaluated by the Subject at 15(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.
units on a scaleADX-102 (0.5%)ADX-102 (0.1%)Vehicle
Ocular Itching Evaluated by the Subject at 15(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.1.662 ± 1.00851.801 ± 0.96011.985 ± 0.9768
PrimaryOcular Itching Evaluated by the Subject at 20(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.

Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.

Time frame:
Efficacy assessment period (Day 1 through Day 15), Day 15 reported.
Reported as:
Mean · units on a scale
Ocular Itching Evaluated by the Subject at 20(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.
units on a scaleADX-102 (0.5%)ADX-102 (0.1%)Vehicle
Ocular Itching Evaluated by the Subject at 20(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.1.152 ± 0.97991.434 ± 0.97731.551 ± 1.0433

Adverse events

Collected over Adverse event data was captured for approximately 5 weeks for each subject during clinical trial participation.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADX-102 Ophthalmic Drops (0.5%)0/53 (0%)0/53 (0%)0/53 (0%)
ADX-102 Ophthalmic Drops (0.1%)0/51 (0%)0/51 (0%)0/51 (0%)
Vehicle of ADX-102 Ophthalmic Drops0/49 (0%)0/49 (0%)0/49 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ADX-102 Ophthalmic Drops (0.5%)ADX-102 Ophthalmic Drops (0.1%)Vehicle of ADX-102 Ophthalmic DropsTotal
<=18 years0000
Between 18 and 65 years514748146
>=65 years2428
Sex: Female, Male
Sex: Female, Male(Participants)ADX-102 Ophthalmic Drops (0.5%)ADX-102 Ophthalmic Drops (0.1%)Vehicle of ADX-102 Ophthalmic DropsTotal
Female40273097
Male13242057
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ADX-102 Ophthalmic Drops (0.5%)ADX-102 Ophthalmic Drops (0.1%)Vehicle of ADX-102 Ophthalmic DropsTotal
Hispanic or Latino45312
Not Hispanic or Latino494646141
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ADX-102 Ophthalmic Drops (0.5%)ADX-102 Ophthalmic Drops (0.1%)Vehicle of ADX-102 Ophthalmic DropsTotal
American Indian or Alaska Native0000
Asian0112
Native Hawaiian or Other Pacific Islander003434
Black or African American18171348
White3533068
More than one race0000
Unknown or Not Reported0022
Iris Color (Right Eye)
Iris Color (Right Eye)(participants)ADX-102 Ophthalmic Drops (0.5%)ADX-102 Ophthalmic Drops (0.1%)Vehicle of ADX-102 Ophthalmic DropsTotal
Black0011
Blue8111029
Brown31292686
Hazel65718
Green85619
Gray0101
Other0000
Iris Color (Left Eye)
Iris Color (Left Eye)(participants)ADX-102 Ophthalmic Drops (0.5%)ADX-102 Ophthalmic Drops (0.1%)Vehicle of ADX-102 Ophthalmic DropsTotal
Black0011
Blue8111029
Brown31292686
Hazel65718
Green85619
Gray0101
Other0000
08

Study locations

5 sites
  • Eye Care Centers Management
    Morrow, Georgia 30260, United States
  • Silverstein Eye Centers
    Kansas City, Missouri 64133, United States
  • Apex Eye Clinical Research
    Mason, Ohio 45040, United States
  • Philadelphia Eye Associates
    Philadelphia, Pennsylvania 19148, United States
  • Total Eye Care
    Memphis, Tennessee 38119, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2016, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2023, 5 years 8 months after primary completion. A results delay was requested in Apr 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2016
First posted
Jan 6, 2017
Start
Dec 2016
Primary completionActual
May 2017
CompletionActual
May 2017
Results delay requested
Apr 6, 2018
Results first posted
Jan 9, 2023
Last update
Jan 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03012165
Collaborators
ORA, Inc.
Responsible party
Sponsor
First posted
Jan 6, 2017
Start date
Dec 2016
Primary completion
May 2017
Completion
May 2017
Results posted
Jan 9, 2023
Last update
Jan 9, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Reproxalap

Start the discussion